Mayo Clinic | Strategic Alliance Partners

January 27, 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

January 27, 2021

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

January 26, 2021

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

January 26, 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

January 22, 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.

January 22, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

January 21, 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

January 21, 2021

Beau Toskich, MD, discusses key results that demonstrate the benefit of personalized dosimetry, and offered advice to fellow clinicians as the field moves toward adopting this radiotherapeutic modality.

January 20, 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

January 20, 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.

January 20, 2021

Beau Toskich, MD, discusses the potential of TheraSphere as a therapy in hepatocellular carcinoma, the importance of utilizing a multidisciplinary approach among novel radiation oncology agents, and his hope for a future prospective clinical trial evaluating Y-90.

January 18, 2021

Rafael Fonseca, MD, weighs the risks and benefits of quadruplet regimens in patient with multiple myeloma.

January 13, 2021

Sikander Ailawadhi, MD, discusses the emergence of T-cell engagers in multiple myeloma.

January 13, 2021

Yi Lin, MD, PhD, discusses CAR T-cell therapy–related toxicities in multiple myeloma.

January 13, 2021

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

January 08, 2021

Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.

January 08, 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

January 06, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses incorporating potential mechanisms of resistance into treatment selection in hepatocellular carcinoma.

January 05, 2021

Sikander Ailawadhi, MD, discusses the integration of selinexor into the treatment landscape of relapsed/refractory multiple myeloma.

January 05, 2021

Yi Lin, MD, PhD, discusses the characteristics of patients who were included in the CRB-401 study examining the CAR T-cell product idecabtagene vicleucel in multiple myeloma.